With the increasing use of nonsteroidal anti-inflammatory drugs (NSAIDs), the incidence of lower gastrointestinal (GI) complications is expected to increase. However, unlike upper GI complications, the burden, pathogenesis, prevention and treatment of NSAID-associated lower GI complications remain unclear. To date, no cost-effective and safe protective agent has been developed that can completely prevent or treat NSAID-related lower GI injuries. Selective COX-2 inhibitors, misoprostol, intestinal microbiota modulation, and some mucoprotective agents have been reported to show protective effects on NSAID-induced lower GI injuries. This review aims to provide an overview of the current evidence on the prevention of NSAID-related lower GI injuries. (Gut Liver 2020;14:179-189) 
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit mucosal prostaglandin production, could induce both upper and lower gastrointestinal (GI) mucosal damages. 1 In the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) trial, NSAIDs use was associated with a higher risk of upper GI bleeding (relative risk [RR], 2.6; 95% confidence intervals [CI], 2.0 to 3.5) than lower GI bleeding (RR, 1.4; 95% CI, 1.0 to 1.9). 2 However, lower GI events still accounted for 40% of all NSAID-related serious GI events. 3 With the increasing use of gastroprotective agents as well as the declining prevalence of Helicobacter pylori infection, the incidence of upper GI complications is generally decreasing but the incidence of lower GI complications is rising. 4, 5 Many of the lower GI complications are related to the use of NSAIDs and aspirin. Even with the concurrent use of gastroprotective agents, up to three-quarters of patients using NSAIDs could still suffer from small intestinal injuries. 6 However, unlike upper GI complications, the burden, pathogenesis, prevention and treatment of NSAIDs-associated lower GI complications remain unclear. 7 To date, there is no evidence-based effective and safe strategy that can completely prevent or treat NSAIDs-related lower GI injury. 7, 8 This review aims to give an overview of the current evidence of potential strategies in the prevention of NSAIDs-related lower GI injury. Details of all studies are presented in Table 1 .
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SELECTIVE COX-2 INHIBITORS
Selective COX-2 inhibitors, with its selectivity on COX-2 inhibition, is one of the major candidates to replace nonselective NSAIDs in reducing the risk of GI injury. Although it has been widely studied in the prevention of upper GI complications, 12, [46] [47] [48] evidences supporting the benefits of selective COX2 inhibitors over nonselective NSAIDs in the lower GI tract were limited.
It was suggested that use of selective COX-2 inhibitors was associated with a reduced incidence of GI perforations, ulcers and bleeds, with less fecal blood loss and fewer endoscopically detectable lesions. 49 Hawkey et al. 10 compared the small-bowel injury of selective COX-2 inhibitor, lumiracoxib, with naproxen and placebo in a double-blind randomized controlled trial (RCT). They found that acute small-bowel injury induced by lumiracoxib is less frequent than with naproxen plus omeprazole and similar to placebo. However, this study included healthy volunteers with short follow up of 16 days only. Another study compared the incidence of small bowel injury, as assessed by video capsule endoscopy, in 408 healthy subjects receiving celecoxib with those receiving ibuprofen plus omeprazole. Celecoxib was 
MISOPROSTOL
It is generally considered that prostaglandins are important in the mediation of inflammation and maintenance of mucosal integrity of the GI tract. 50 While inhibition of prostaglandin synthesis through COX is one of the major mechanisms of NSAIDs induced GI tract injury, 51 supplementation with misoprostol, a prostaglandin analog, may be effective in protecting against NSAIDs induced enteropathy. 50 Morris et al. 16 reported that high dose (1,200 µg) misoprostol therapy was associated with an improvement in anemia with an increase of hemoglobin in patients with proven NSAID enteropathy in a retrospective study of 21 patients. Bjarnason et al. 14, 52 also found that co-administration of misoprostol with NSAIDs alleviated the indomethacininduced increase in intestinal permeation. However, the study of Davies et al. 15 showed that the protective effects of misoprostol (800 µg) on the intestinal permeability co-administration with indomethacin was limited. It was suggested that prostaglandin alleviation of NSAID-induced intestinal permeability may be dose-dependent or that intestinal permeability may only be partially mediated by reduced mucosal prostaglandins. 53 This doseresponse effect was also found in study comparing the efficacy of three misoprostol dosing regimens in the prevention of gastric and duodenal ulcers associated with long-term NSAIDs. 17, 18 The protective effects of misoprostol were further demonstrated in studies evaluating small intestine damage by capsule endoscopy. Watanabe et al. 19 reported that misoprostol (200 µg given 4 times daily) improved the mucosal lesions found in the small intestine by capsule endoscopy in a case series of 11 patients who had developed gastric ulcers induced by low-dose enteric-coated aspirin. A pilot RCTs by Fujimori et al., 20 involving 34 healthy volunteers, showed that misoprostol (200 µg given 3 times daily) co-therapy reduced the incidence of smallintestinal mucosal breaks induced by a 2-week administration of diclofenac sodium. Recently, Kyaw et al. 21 performed an RCT of 84 aspirin users with small bowel bleeding who required aspirin therapy and found that misoprostol (200 µg given 4 times daily) for 8 weeks was superior to placebo in healing of small bowel ulcers. Similar results were also reported in another randomized trial by Taha et al. 22 Though the potential protective effects of misoprostol were observed in these studies, large clinical trials with long-term outcomes are lacking. Furthermore, significantly increased risk of drug-related adverse effects like abdominal pain, nausea or vomiting, diarrhea and high dropout rate related to the use of misoprostol were observed in clinical trials.
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COX-INHIBITING NITRIC OXIDE DONORS (CINODS)
It has been shown that nitric oxide (NO) plays a key role in the maintenance of the GI mucosa. 54, 55 NO and prostaglandin showed similar gastroprotective actions that they are both capable of modulating mucosal blood flow, mucus release, and repair of mucosal injury. 56, 57 Hence, cyclooxygenase inhibiting nitric oxide donators (CINODs) are a new class of antiinflammatory and analgesic drugs, in which NO is coupled to an NSAID, could potentially minimize GI toxicity of traditional NSAIDs. 57, 58 In early animal studies, though prostaglandin was still suppressed, NO-releasing derivatives of a wide range of NSAIDs, including aspirin, flurbiprofen, naproxen, and diclofenac, have been shown to minimize the GI injury. [58] [59] [60] [61] [62] Different from conventional NSAIDs or selective COX-2 inhibitors, which exacerbate experimental colitis in rats 63 or inflammatory bowel disease in humans, 64 NO-releasing diclofenac was found to be well tolerated by rats with colitis. 65 Several clinical studies have also shown consistently that CINODs cause less upper GI damage.
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However, there is no clinical studies that evaluate the effects of CINODs in the lower GI tract.
INTESTINAL MICROBIOTA MODULATION
Accumulating evidences suggest that intestinal bacteria may play a significant role in the pathogenesis of small-bowel dam-age induced by NSAIDs and that enterobacterial translocation into the mucosa represents the first step of a series of events leading to gross lesion formation. 66, 67 It has been reported that germ-free mice were resistant to NSAIDs related intestinal damage. 68, 69 However, when germ-free mice were colonized with jejunal bacteria from PPI-treated rats, the severity of NSAIDinduced intestinal injury increased. 70 Therefore, modulating intestinal microbiota could be a new strategy in the prevention of NSAID-induced intestinal damage. 67, 71 In keeping with this, several studies reported that antibiotics could attenuate NSAIDs induced enteropathy. 66 A resent animal study showed that rifaximin treatment significantly prevents indomethacin-induced intestinal damage following with a decrease in tissue inflammation, oxidative stress and digestive bleeding as well as reversal of NSAID-induced alterations in bacterial population. 72 Colucci et al. 73 examined the pathophysiology of NSAID-associated intestinal lesions in a rat model and found that rifaximin prevents diclofenac-induced enteropathy through both anti-bacterial and anti-inflammatory activities.
Other antibiotics like metronidazole, tetracycline, kanamycin, neomycin plus bacitracin and streptomycin were also reported to reduce the risk of NSAID induced enteropathy. 26, [74] [75] [76] In addition, rifaximin also demonstrated protective effect in patients receiving long-term PPIs treatment, which eradicated 87% to 91% of cases of small intestinal bacterial overgrowth. 77 Nevertheless, current evidences supporting the effects of antibiotics in preventing NSAID-induced enteropathy are still weak and most of them were from animal models. Even though antibiotics showed protective effects on NSAIDs/PPIs induced enteropathy, the long-term efficacy and safety has not been confirmed and further large long-term clinical studies are necessary. Probiotics is another approach in modulating the composition of intestinal flora and has been used in treating several GI disorders like inflammatory bowel diseases, 78 irritable bowel syndrome, 79 infectious diarrhea and antibiotic-induced diarrhea. 80, 81 It has been suggested that probiotics could also protect against NSAID-induced enteropathy by modulating the intestinal microbiota. 82 Kinouchi et al. 74 found that the metabolites of Lactobacillus acidophilus and Bifidobacterium adolescentis inhibited ileal ulcer formation by repressing unbalanced growth of the intestinal microflora and lipid peroxidation in rats. NSAIDinduced small bowel injury in rats could be alleviated after restoring small intestinal Actinobacteria through administration of selected commensal bacteria during treatment with PPI and NSAIDs. 70 It was also confirmed in a double-blind, cross-over study of 20 healthy volunteers taking the probiotic mixture (VSL#3) or placebo for 21 days, and found that treatment with VSL#3 before and during indomethacin therapy significantly reduces the intestinal inflammation. 27 A pilot randomized trial of 35 patients who took low-dose enteric-coated aspirin for more than 3 months plus omeprazole, also found that co-administration of Lactobacillus casei could decrease the number of mucosal breaks under capsule endoscopy. 28 However, the quality of evidence on protective effects of probiotics on NSAIDinduced enteropathy are still low and further clinical trials are needed.
ROLE OF PPIs
Gastroprotective agents, especially PPIs, are typically coprescribed to protect the upper GI tract from NSAIDs induced mucosal injury, which was also recommended by guidelines. 83 By suppressing gastric acid secretion, PPIs are effective in decreasing the risk of NSAIDs induced upper GI mucosal damage and bleeding, presumably by raising the pH of the stomach. 84 However, lower GI bleeding could be not protected by PPIs, 2 and emerging evidences further indicate that PPI may increase the risk of NSAIDs induced small bowel damage and bleeding. 70, 85, 86 A similar exacerbation of NSAIDs induced small bowel damage was also observed in H2 receptor antagonists. 85 It was suggested that long term use of PPIs may exacerbate NSAIDs induced small bowel injury by altering intestinal microbiota (dysbiosis) following acid suppression, 7, 70 which is supported by small intestinal bacterial overgrowth observed in patients with long-term use of PPIs. 77, 87 A recent multicenter case-control study found that the use of PPIs remained an independent risk factors for mid GI bleeding (adjusted OR, 1.94; p=0.034) even after adjusting for propensity score. 88 Thus, the use of PPIs is considered to be an independent risk factor associated with NSAID-associated enteropathy and should be used cautiously.
MUCOPROTECTIVE AGENTS 1. Rebamipide
Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is a mucosal protective drug that has been clinically used for treating gastritis and peptic ulcers. 30, 89 Studies have shown that rebamipide is effective to alleviate the NSAIDs induced injury of GI tract, and more recently, the small intestine. 34, 85 Rebamipide promotes the production of endogenous prostaglandins and modulates the composition of small intestinal microbiota, which supports its efficacy on NSAID-induced small intestinal damage. [90] [91] [92] Small RCTs of healthy subjects supported that rebamipide had the potential to reduce NSAID-induced small intestinal injury. 29, [31] [32] [33] 37 Kurokawa et al. 35 performed a multicenter study involving 61 patients who had received more than 3 months of low dose aspirin and/or NSAID to take rebamipide (100 mg 3 times daily for 4 weeks) or placebo and found that rebamipide had the protective effect for NSAIDs-induced enteropathy by reducing the number of small intestinal ulcers and erosions as evaluated by capsule endoscopy. Another small multicenter study by Watanabe et al. 36 also found that 8 weeks of highdose rebamipide (300 mg 3 times daily) significantly decreased the number of mucosal breaks and improved intestinal dam-age severity. However, Ota et al. 37 reported that standard-dose rebamipide (100 mg 3 times daily) was sufficient for preventing mucosal injury of the small intestine induced by low-dose aspirin, indicating that high-dose rebamipide (300 mg 3 times daily) may not be necessary. A systematic review and meta-analysis 34 including 15 RCTs and 965 individuals, provided consistent results that rebamipide is effective and safe for defending against NSAID-induced lower GI injuries. However, most studies are with small sample size and short-term follow-up.
Irsogladine
Irsogladine, a phosphodiesterase inhibitor, is currently used as one of the anti-ulcer or gastroprotective agents for the treatment of gastric ulcer and gastritis. 93 Irsogladine could also prevent NSAIDs or aspirin-induced peptic ulcer and gastritis. 41 Furthermore, it has been reported that, in animal research, irsogladine also possessed protective effects against NSAID-induced small intestinal lesions. 85, 94 This protective effect was further confirmed in clinical studies. The study by Kuramoto et al. 38 involving 32 healthy volunteers, found that co-administration of irsogladine for 14 days protected against NSAID-induced mucosal injuries throughout the GI tract, from esophagus to small intestine, which was significantly better than omeprazole. The result was consistent in the study of Isomura et al. 39 that co-therapy of irsogladine for 4 weeks was effective for reducing NSAID-induced small-intestinal mucosal injury compared with control, in which 41 patients taking conventional NSAIDs for more than 4 weeks were enrolled. Irsogladine also presented treatment effects which significantly decreased the number of small intestinal lesions induced by NSAIDs. 40 
Other
Apart from the above agents, there are several other drugs such as sulphasalazine, 42 ecabet sodium, 43 egualen sodium, 44 curcumin, 95, 96 and muscovite, 45 which were reported to have a preventive effect on NSAIDs-induced small intestine injury. However, data is very limited for these agents.
SUMMARY
So far, effective prevention and treatment of NSAID-associated lower GI injury are lacking. Though various agents including selective COX inhibitors, misoprostol, antibiotics and mucoprotective agents have been considered as candidates for NSAIDinduced intestinal injury, they are not properly evaluated in clinical trials. High-quality well-designed randomized, placebocontrolled trials with long-term follow up are needed to verify the efficacy of potential agents in preventing NSAID-associated lower intestinal injury.
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